Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 90

Using autologous cell therapy to treat knee osteoarthritis pain and inflammation

Official title: Safety and Effectiveness of Autologous Regenerative Cell Therapy on Pain and Inflammation Associated With Osteoarthritis of the Knee

Run by VivaTech International, Inc. · NCT02844751 · Data updated 2026-11-12

This study is testing if a new cell therapy using your own body’s cells can help relieve pain and swelling in people with knee osteoarthritis.

More Osteoarthritis trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 90 Years
SexAll
Enrollment4000 (estimated)
SponsorVivaTech International, Inc.
Industry-sponsored
Locations1 site (Grove City, Pennsylvania)
StatusRecruiting
StartedJuly 2015
Main results expectedAugust 2026
Study endsAugust 2026
Registry record updatedOctober 14, 2025
Trial IDNCT02844751 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-90 with grade 2 or higher osteoarthritis of the knee and a history of knee pain for over 6 months.

Probably not a fit

Patients with recent cancer diagnoses, significant cardiovascular issues, or other serious health conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study aims to evaluate the safety and effectiveness of autologous regenerative cell therapy for patients suffering from knee osteoarthritis. It involves a prospective open-label design with an initial cohort of 50 patients receiving injections of autologous Stromed and Platelet Rich Plasma (PRP) to alleviate pain and inflammation. Patient outcomes will be monitored through MRI scans, laboratory tests for inflammation markers, and various questionnaires assessing knee function and quality of life over a follow-up period of up to 6 months. The study will eventually expand to include a larger sample size of 4,000 patients for further validation.

Why it matters

Potential benefit: If successful, this therapy could significantly reduce pain and inflammation in patients with knee osteoarthritis, potentially delaying the need for knee replacement surgery.

How similar studies have gone: While the use of autologous cell therapies is gaining traction, this specific approach is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients with indication of Osteoarthritis, grade 2 or more. Can be from degeneration or chronic injury.
2. Patients range from 18-90 years of age.
3. Patients must be able to comply with treatment plan, laboratory tests and periodic interviews.
4. Patients with adequate renal function, Creatinine ≤ 1.5 mg/dl.
5. Patients with adequate cardiac and respiratory function.
6. Patients with adequate blood coagulation activity, PT(INR) \< 1.5, APTT
7. Patients must have adequate immune system function, with no known immunodeficiency disease.
8. Greater than 6 months knee pain on the index side (left or right knee).

Exclusion Criteria:

1. Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
2. Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke).
3. Diagnosis of a transient ischemic attack in the 6 months prior to screening.
4. Patients infected with hepatitis B, C or HIV.
5. Patients with Body Mass Index (BMI) \> 40kg/m2
6. Presence of active infection.
7. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study.
8. Conditions/therapies/factors which could confound or interfere with the evaluation of pain/mobility including, but not limited to:

   1. Knee instability.
   2. A varus/valgus deformity of more than 10o, a deformity requiring osteotomy or complex surgery.
   3. Gout or pseudo gout
   4. Treatments with strong opioid drugs in the previous 4 weeks for other pain rather than knee osteoarthritis
   5. Corticosteroid injection at treatment site within 1 month
   6. Consistent use of NSAIDs within 48 hours of procedure.

Where it's running

  • VivaTech International, Inc.
    Grove City, Pennsylvania, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.